FDA Inspection 858696 — The Center for Reproductive Endocrinology

The Center for Reproductive Endocrinology — FEI 3003927090

The FDA completed an inspection of The Center for Reproductive Endocrinology on December 13, 2013 in Dallas, TX. The inspection was classified VAI (Voluntary Action Indicated — objectionable conditions were found but do not meet the threshold for regulatory action). 4 citations were issued during this inspection. Product area: Biologics.

Inspection Details

Classification
Voluntary Action Indicated (VAI) (VAI)
End Date
December 13, 2013
Fiscal Year
2014
Product Type
Biologics
Project Area
Human Cellular, Tissue, and Gene Therapies
Location
Dallas, TX (United States)

Citations

IDCFRDescription
1221321 CFR 1271.47(a)Testing, screening, donor eligibility procedures
1224221 CFR 1271.55(c)Name and personal info on accompanying records
1224621 CFR 1271.55(d)(1)(iii)Documentation--determination, by whom, date
1227021 CFR 1271.65(a)Improper release prevention--storage, I.D.